Skeletal Actin/cmv Hybrid Enhancer/promoter Improved Muscle-derived Expression of Human Coagulation Factor Ix from A

Updated information and services can be found at: (517 articles) Gene Therapy Articles on similar topics can be found in the following Blood collections

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  R. Herzog,et al.  Adeno-Associated Virus-Mediated Gene Transfer of Factor IX for Treatment of Hemophilia B by Gene Therapy , 1999, Thrombosis and Haemostasis.

[3]  C. Ordahl,et al.  Poly(ADP-Ribose) Polymerase Binds with Transcription Enhancer Factor 1 to MCAT1 Elements To Regulate Muscle-Specific Transcription , 1999, Molecular and Cellular Biology.

[4]  L. Villarreal,et al.  Adeno-associated virus vectors can be efficiently produced without helper virus , 1998, Gene Therapy.

[5]  R. Ljung,et al.  Prophylactic treatment in Sweden — overtreatment or optimal model? , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  R. Ljung.  Can haemophilic arthropathy be prevented? , 1998, British journal of haematology.

[7]  G. Vrbóva,et al.  Myosin regulatory elements as vectors for gene transfer by intramuscular injection , 1998, Gene Therapy.

[8]  V. Sandig,et al.  Reactivation of the Previously Silenced Cytomegalovirus Major Immediate-Early Promoter in the Mouse Liver: Involvement of NFκB , 1998, Journal of Virology.

[9]  J. Escobedo,et al.  Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Bohl,et al.  Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. , 1997, Human gene therapy.

[11]  J. Chamberlain,et al.  Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy , 1997, Neuromuscular Disorders.

[12]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[13]  James M. Wilson,et al.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Marshall,et al.  Optimization of plasmid vectors for high-level expression in lung epithelial cells. , 1997, Human gene therapy.

[15]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[16]  B. Byrne,et al.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Samulski,et al.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.

[18]  K. Kurachi,et al.  Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. , 1996, Human gene therapy.

[19]  M. Sands,et al.  Successful expression of human factor IX following repeat administration of adenoviral vector in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  K. Kurachi,et al.  Role of Intron I in Expression of the Human Factor IX Gene (*) , 1995, The Journal of Biological Chemistry.

[21]  K. Kurachi,et al.  Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. , 1994, Gene therapy.

[22]  R. Naviaux,et al.  Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Susumu Tonegawa,et al.  RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.

[24]  N. Rosenthal,et al.  The myosin light chain enhancer and the skeletal actin promoter share a binding site for factors involved in muscle-specific gene expression , 1991, Molecular and cellular biology.

[25]  L. Kedes,et al.  Nucleotide sequence and expression of the human skeletal alpha-actin gene: evolution of functional regulatory domains. , 1988, Genomics.

[26]  J. Mar,et al.  A conserved CATTCCT motif is required for skeletal muscle-specific activity of the cardiac troponin T gene promoter. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Cooper,et al.  Analysis of the upstream regions governing expression of the chicken cardiac troponin T gene in embryonic cardiac and skeletal muscle cells , 1988, The Journal of cell biology.

[28]  L. Kedes,et al.  Multiple 5'-flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression , 1987, Molecular and cellular biology.

[29]  K. Kurachi,et al.  Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). , 1985, Biochemistry.

[30]  K. Kurachi,et al.  Isolation and characterization of a cDNA coding for human factor IX. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Edna,et al.  Quantitative Analysis of the Human a-Skeletal Actin Gene in Transgenic Mice * , 2001 .

[32]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.

[33]  M. Kay,et al.  Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors , 1999, Nature Medicine.

[34]  Xiao Xiao,et al.  New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors , 1997, Nature Medicine.